MDS 004

Known as: MDS-004

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2010

2010

Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.

P. FenauxA. Giagounidis E. Hellström-Lindberg
2010
Corpus ID: 68054928

6598 Background: In a multicenter placebo-controlled study, LEN (10 mg/day for 1–21 days or 5 mg/day for 1–28 days; 28-day cycle…